Based on the status of hormone receptors (ER and PR) and HER2, four principal molecular subtypes [luminal-A, -B, HER2-enriched and triple-negative breast cancer (TNBC)] have been characterized and are routinely used to predict prognosis and optimize adjuvant therapy in breast cancer [37]. The gene discussed is PGR; the disease is triple-negative breast carcinoma.